TARGETID

T38950

FORMERID

TTDS00091

UNIPROID

CD33_HUMAN

TARGNAME

Myeloid cell surface antigen CD33 (CD33)

GENENAME

CD33

TARGTYPE

Successful target

SYNONYMS

Siglec-3; Sialic acid-binding Ig-like lectin 3; SIGLEC3; Gp67

FUNCTION

Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state.

PDBSTRUC

6D4A; 6D49; 6D48; 5J0B; 5J06

BIOCLASS

Immunoglobulin

SEQUENCE

MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSEVRTQ

DRUGINFO

Gemtuzumab ozogamicin

DRUGINFO

Vadastuximab talirine

DRUGINFO

Actimab-A

DRUGINFO

BI-836858

DRUGINFO

Anti-CD33 CAR-T cells

DRUGINFO

CART33 cells

DRUGINFO

CD33-specific gene-engineered T cells

DRUGINFO

GTB-3550

DRUGINFO

HuM-195-Ac-225